... focused on development and commercialization of products for treatment of attention deficit hyperactivity disorder (ADHD) Bosulif (bosutinib), a tyrosine kinase inhibitor, was approved by the FDA last year as a second line treatment for myelogenous ...
http://seekingalpha.com/article/1330471-where-is-pfizer-heading-with-the-patent-cliff?source=feed
http://seekingalpha.com/article/1330471-where-is-pfizer-heading-with-the-patent-cliff?source=feed
